Collaboration and License Agreements and Supply Agreements (Tables)

3 Months Ended

Mar. 31, 2024

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

In accordance with the collaboration, license and supply agreements, the Company recognized revenue as follows:

	Three Months Ended
	March 31,
	2024		2023
	(in thousands)
Merck Sharp & Dohme Corporation (“Merck”)	$	6	$	2,553
Astellas Pharma Inc. (“Astellas”)		11,385		6,272
Tasly Biopharmaceuticals Co., Ltd. (“Tasly”)		970		-
Vaxcyte, Inc. ("Vaxcyte")		647		675
Bristol Myers Squibb Company (“BMS”)		-		3,166
Merck KGaA, Darmstadt, Germany (operating in the United    States and Canada under the name “EMD Serono”)		-		8
Total revenue	$	13,008	$	12,674

Summary of Deferred Revenue Balance

The following table presents the changes in the Company’s deferred revenue balance from the agreements during the three months ended March 31, 2024:

	Three Months Ended
	March 31, 2024
	(in thousands)
Deferred revenue—December 31, 2023	$	74,045
Additions to deferred revenue		-
Recognition of revenue in current period		(7,230	)
Deferred revenue—March 31, 2024	$	66,815

Vaxcyte, Inc.

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Vaxcyte agreements were as follows:

	Three Months Ended
	March 31,
	2024		2023
	(in thousands)
Research and development services	$	647	$	504
Materials supply		-		171
Total revenue	$	647	$	675

2020 Merck Master Services Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:

	Three Months Ended
	March 31,
	2024		2023
	(in thousands)
Research and development services	$	6	$	125
Materials supply		-		2,428
Total revenue	$	6	$	2,553

Astellas License and Collaboration Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Astellas Agreement were as follows:

	Three Months Ended
	March 31,
	2024		2023
	(in thousands)
Ongoing performance related to    unsatisfied performance obligations	$	7,230	$	2,572
Research and development services		1,623		1,157
Financing component on unearned revenue		2,160		2,543
Materials supply		372		-
Total revenue	$	11,385	$	6,272

Tasly License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Summary of Recognized Revenue

Revenues under the Tasly agreements were as follows:

	Three Months Ended
	March 31,
	2024		2023
	(in thousands)
Research and development services	$	33	$	–
Materials supply		937		–
Total revenue	$	970	$	–